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Abstract
About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers
are required to better manage therapy options. The purpose of this study is to develop and validate a novel gene-
expression signature that can predict tumor recurrence of stage I NSCLC patients. Cox proportional hazards regression
analysis was performed to identify recurrence-related genes and a partial Cox regression model was used to generate a
gene signature of recurrence in the training dataset 2142 stage I lung adenocarcinomas without adjunctive therapy from
the Director’s Challenge Consortium. Four independent validation datasets, including GSE5843, GSE8894, and two other
datasets provided by Mayo Clinic and Washington University, were used to assess the prediction accuracy by calculating the
correlation between risk score estimated from gene expression and real recurrence-free survival time and AUC of time-
dependent ROC analysis. Pathway-based survival analyses were also performed. 104 probesets correlated with recurrence in
the training dataset. They are enriched in cell adhesion, apoptosis and regulation of cell proliferation. A 51-gene expression
signature was identified to distinguish patients likely to develop tumor recurrence (Dxy=20.83, P,1e-16) and this
signature was validated in four independent datasets with AUC .85%. Multiple pathways including leukocyte
transendothelial migration and cell adhesion were highly correlated with recurrence-free survival. The gene signature is
highly predictive of recurrence in stage I NSCLC patients, which has important prognostic and therapeutic implications for
the future management of these patients.
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Introduction
Lung cancer is still the leading cause of cancer-related death for
both men and women in the United States, though therapeutic
outcomes have gradually improved. In 2010, there were estimated
222,520 new cases of lung cancer diagnosed and only 15% of those
will be alive after 5 years [1]. Non-small cell lung cancer (NSCLC)
constitutes about 85% of all lung cancers, with small cell
carcinoma making up the remaining 15%. About 25% to 30%
of patients with NSCLC have stage I disease and receive surgical
intervention alone. Despite undergoing curative surgery, more
than 25% of patients with stage I NSCLC will die from recurrent
disease within five years [2,3]. Adjuvant cisplatin based chemo-
therapy in stage I–III NSCLC improves survival modestly
following surgical resection [4,5,6]. Cancer and Leukemia Group
B (CALGB) 9633, a phase III study that compared adjuvant
therapy with carboplatin/paclitaxel versus surgery alone for
completely resected stage IB NSCLC, showed a significant
survival benefits to adjuvant therapy after 2.8 years of median
follow-up [7] but not after 4.5 years of follow-up [8]. Reliable
clinical or molecular prognostic factors, as well as guidelines for
treatment of recurrent stage I NSCLC have not been well
elucidated. Because of heterogeneity in recurrence rates among
cancer patients with the same stage, it is critical to isolate a reliable
molecular signature in tumors that could be used to identify those
who are likely to develop recurrent disease and would thus benefit
from adjuvant therapy. Moreover, identification of genes and
molecular pathways critical for development of metastasis could
lead to advances in therapeutics.
Advances in human genomics and proteomics have generated
lists of candidate biomarkers with potential clinical values. Gene
expression profiling has been used to characterize prognosis in
lung cancer, mostly using overall survival (OS) rather than tumor
recurrence as an end point [9,10,11,12,13,14]. However, the
identified survival-related genes lacked consistency among these
studies, likely due to limited patient samples, disease heterogeneity,
and/or technical factors such as differences in microarray
platforms and specimen processing. Integrating microarray data
from multiple studies to increase sample size holds promise for the
development of more robust prognostic tests. We thus conducted a
meta-analysis of seven data sets to search for differentially
expressed genes related to overall survival time [15] and identified
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30880a 64-gene expression signature that is highly predictive of OS of
stage I NSCLC patients. Our results indicate that gene expression
signatures are useful in predicting survival of stage I lung cancer,
and meta-analysis of microarray datasets increases statistical power
for detecting survival-related differentially expressed genes.
In investigations of the effectiveness of adjuvant therapy, OS is
considered as the gold standard end point. However, the
disadvantage of OS is that it requires an extended follow-up.
Recently several studies explored disease-free survival (DFS) as a
possible alternative end point of OS. Some evidences had been
offered for the use of DFS as a surrogate for OS in colorectal
cancer, breast cancer and stomach cancer [16]. In these studies,
the Pearson’s correlation between 5-year OS and 3-year DFS was
0.97 and Spearman’s rank correlation was 0.92; the Pearson’s
correlation between hazard ratios for OS and DFS was 0.85 and
Spearman’s rank correlation was 0.87.
In this study, we conducted a meta-analysis of microarray
datasets from different institutions to develop and validate a novel
gene-expression signature that can accurately predict tumor
recurrence of stage I NSCLC patients. The identified signature
has potential to refine the clinical practice in the management
patients with resected NSCLC.
Methods
Data Collection
The Director’s Challenge Consortium for the Molecular
Classification of Lung Adencarcinoma (‘‘Director’s Challenge
Consortium’’) collected more than 300 lung adenocacinoma
samples from four institutions (HLM, MICH, DFCI, and
MSKCC) along with pertinent clinical data [17]. In our study
we used a total of 142 patient samples with stage I lung
adencarcinoma, which were not given adjunctive chemotherapy
or radiotherapy, as training samples to identify a gene-expression
signature for recurrence free survival. The data were downloaded
from https://array.nci.nih.gov/caarray/project/details.action?
project.experiment.publicIdentifier=jacob-00182.
Other four independent datasets (datasets 2–5) were used as
testing samples for validation of the identified signature. Dataset 2
included 46 stage I lung adenocarcinomas. Dataset 3 included
both adenocarcinomas and squamous cell carcinomas with 64% of
138 samples being stage I tumors. It is important to know whether
our developed signature is applicable to other cancer subtype such
as squamous cell carcinomas or not. Dataset 2 and 3 were
downloaded from GEO database (GSE5843 and GSE8894).
Dataset 4 was generated by Mayo Clinic and included 54 stage I
NSCLC in never smokers, and most of them were adenocarcino-
mas. Dataset 5 was generated by our own group at Washington
University which was used to identify our 64-gene signature for
overall survival (the data was deposited in GEO database as
GSE6253) [15]. All patients in these validation sets were not given
adjuvant chemotherapy or radiotherapy.
PRISMA 2009 flow diagram regarding the dataset selection is
showed in Figure S1. Details of the clinical information for the
subjects in each dataset are described in Table 1. The endpoint
was time to recurrence, defined as the time from surgical resection
to the first evidence of tumor recurrence (local, regional or distant).
Patients were censored from the recurrence analysis at the earliest
of the following time points: death, development of second
primary NSCLC, or last medical contact. The involved micro-
array platforms included Affymetrix Hu133A (dataset 1), Hu133-
plus2 (dataset 3), HG_U95Av2 array (dataset 5), 22 K Operon
Human Genome Oligo Set v2.1 (http://www.operon.com)
(dataset 2) and Illumina DASL assay (dataset 4).
Data Processing
Even though the training dataset is from one study, the samples
were collected and profiled in four different institutions. Systematic
differences in gene expression from these institutions may be
remarkable, which would compromise the integrity of the data
from different labs. The distance-weighted discrimination (DWD)
method (https://genome.unc.edu/pubsup/dwd/index.html) was
used to identify and adjust systematic biases that were present
within this microarray dataset. The DWD method corrects for
Table 1. Clinical summary of patients in the analyzed datasets.
Dataset 1 Dataset 2 Dataset 3 Dataset 4 Dataset 5
Total number of samples 142 46 138 54 36
Mean age (range) 65 (35–85) 63 (36–78) 61 (31–82) 69 (32–89) 66 (48–81)
Sex
male 80 33 104 9 20
female 62 13 34 45 16
Mean follow-up (months)
Total DFS 57 39 35 48 38
No recurred 69 63 54 55 51
Recurred 27 35 16 33 22
Stage
IA 70 16 — 27 0
IB 72 30 — 27 36
Histological type
ADC 142 46 62 49 14
S C C 007 6 11 8
Others 0 0 0 4 4
doi:10.1371/journal.pone.0030880.t001
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hyperplane between the two batches and adjusting the data by
projecting the different batches on the DWD plane, finding the
batch mean, and then subtracting out the DWD plane multiplied
by this mean [18].
Statistical analysis
Identify differentially expressed genes related to
recurrence. Multivariate Cox proportional hazards regression
analyses (adjusted for age, gender, and cancer stage) with 10,000
bootstrap resampling were performed for each gene using all of the
142 samples in Dataset 1. The proportional hazards assumption
for these variables was investigated by examining the scaled
Schoenfeld residuals. The categorical variables gender and cancer
stage displayed significant deviation from the proportional hazards
assumption and were thus taken as strata in regression models.
The genes were then ranked according to the bootstrap
frequencies of P,0.01 for their gene expression in regression
models. We then performed GO term enrichment analysis on
these differentially expressed genes using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
bioinformatics resource (http://david.abcc.ncifcrf.gov/home.jsp).
Similar statistical analyses were detailed in a previous study [15].
Define a gene-expression signature for recurrence. The
following survival analyses were also based on all of the 142
samples in Dataset 1. Partial Cox regression method was
performed to construct predictive components [19]. These
components were then used in the Cox model for building
predictive models for recurrence-free survival of cancer patients.
The principle components were chosen in the model to maximize
Somers’ Dxy rank correlation. The risk scores were calculated by
f(x)~
X G
j~1
b
 
j (Xj{ x x:j), where G represents the number of genes;
b
 
j represents the estimated coefficient of the jth gene; Xj represent
gene expression levels of the jth gene in all the samples,
 x x:j~1=n
Xn
i~1 xij where n is sample size and xij is the gene
expression level of gene j from sample i. All the samples were
classified into high and low risk groups according to the risk scores.
Patients with risk scores less than zero potentially have long-term
recurrence-free survivals and those larger than zero have short-
term recurrence-free survival after surgical resection. To choose an
appropriate subset of genes for signature, we carried out a forward
selection procedure to optimize a gene-expression signature: 1)
increase one gene each time based on the rank of genes that were
identified in the above bootstrap analyses; 2) perform the partial
Cox regression analysis and obtain the prediction accuracy using
the chosen subset of genes; and 3) repeat steps 1 and 2 until the
prediction accuracy is maximized. The prediction accuracy
(discrimination ability) was assessed by Somers’ Dxy rank
correlation of estimated risk score and real survival time.
Somers’ Dxy is related to the C-index by Dxy=2(C-0.5). C is
the corresponding receiver operating characteristic (ROC) curve
area, which is a graphical representation of the pairs of false-
positive test results (specificity) and true-positive test results
(sensitivity) for the realizations of a quantitative test.
To identify a gene signature robustly predicting time to
recurrence, leave-one-out cross-validation (LOOCV) was used.
Briefly, 142 iterations of the above forward selection procedure
were performed so that each sample was left out once with a set of
genes in relation to time to recurrence calculated at each iteration.
The frequency of the genes occurring in the signatures were
ranked to identify genes that consistently, and robustly, correlated
with outcome. The genes that passed the set criterion (frequency
.50%) were selected to comprise the final signature.
To evaluate the predictive performance of the proposed gene
signature, we employed time-dependent ROC analysis for censored
data and area under the curve (AUC) as our criteria to assess
recurrence predictions. The time-dependent sensitivity and speci-
ficity functions are defined as: sensitivity(c,t)~PfXwcjD(t)~1g
and specificity(c,t)~PfXwcjD(t)~0g. The corresponding
ROC(t) curve for any time t is defined as the plot of {sensitivity
(c, t)} versus {1 – specificity(c, t)}, with cutoff point c varying. X is
the covariate and D(t) is the event indicator (here, recurrence) at
time t. The area under the curve, AUC(t), is defined as the area
under the ROC(t) curve. A nearest neighbor estimator for the
bivariate distribution function is used for estimating these
conditional probabilities accounting for possible censoring [20].
AUC can be used as an accuracy measure of the diagnostic marker;
the larger the AUC, the better the prediction model. AUC=0.5
indicates no predictive power, whereas AUC=1 represents perfect
predictive performance. Kaplan-Meier survival analyses were
implemented after the samples were classified into two risk groups.
Differences of the recurrent risk between the two risk groups were
assessed using the Mantel-Haenszel log rank test. The larger area
between the two risk groups and its associated smaller p value from
the Mantel-Haenszel log rank test implicate a better classification
model. Somers’ Dxy rank correlation of estimated risk score and
real survival time were also calculated.
Validate the signature in four independent microarray
datasets. After the signature was defined, we evaluated it in
four independent datasets (i.e., Datasets 2–5). The expression data
of genes in the signature were used to estimate risk score for each
samples in the independent datasets. Please note that the gene
numbers used to estimate risk score were different because of the
different microarray platforms used in the training dataset and
testing datasets. The Partial Cox regression were redone for each
dataset to get the estimated coefficient of each gene in order to
calculate risk score for each sample. Somers’ Dxy rank correlation
of estimated risk score and real survival time were calculated and
time-dependent ROC analysis were performed for each testing
dataset.
Identify significant pathways relatedto recurrence. Partial
Coxregressionmethodwas alsoperformed for eachKEGG pathway.
T h er i s ks c o r e sw e r ec a l c u l a t e du s i n gt h eg e n es e t si ne a c hp a t h w a y .
All the samples were classified into high and low risk groups
according to the risk scores. Differences in recurrent risk between the
two risk groups were assessed using the Mantel-Haenszel log rank
test. P values less than 10
24 were use to define significant pathways.
All of the data analyses were implemented using the R statistical
package (www.r-project.org).
Results
Differentially expressed genes associated with recurrence
To identify a gene expression signature of tumor recurrence, we
analyzed a training set of 142 stage I lung adencarcinomas from
the Director’s Challenge Consortium, including 70 with stage IA
(T1N0M0) disease and 72 with stage IB (T2N0M0). None of
the142 patients in the analysis were given adjuvant chemotherapy
or radiotherapy. Multivariate Cox proportional hazards regression
analyses with bootstrap resampling approaches were performed
for each gene to determine if it was significantly associated with
cancer recurrence. We identified 104 probesets from 98 known
genes with bootstrap frequencies greater than 80% for their gene
expression in regression models (Table S1). Eighteen probesets
were associated with good outcome (hazard ratio ,1.0), that is,
patients with higher expressions of these genes tend to have longer
recurrence free survival. In contrast, the other 86 probesets were
Signatures Predict Lung Cancer Recurrence
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expression of these genes result in shorter recurrence free survival
of stage I patients. GO term enrichment analysis on these
differentially expressed genes indicated one third of the genes we
identified are potentially involved in known cancer-related
pathways. Among them, B4GALT1, CELSR1, CLDN4, CLDN9,
COL2A1, ALCAM, ICAM4, MUC5AC and THBS1 are related to cell
adhesion; NLRP2, CGB, LUC7L3, ELMO2, EIF2AK2, IFI6,
MUC5AC, NFKBIL1, PPT1, PACS2, RHOT1, THBS1 are related
to apoptosis; and CLEC11A, B4GALT1, BMP2, EIF2AK2, FABP3,
FGFR2, ING1, ITCH, MUC5AC, NFKBIL1, THBS1, TCF3 are
related to regulation of cell proliferation.
Identification of a gene signature for recurrence in the
training set
Next, we attempted to identify a manageable, robust set of genes
whose expression could be used to predict primary tumors likely to
recur. We employed a partial Cox regression analysis with leave-
one-out cross-validation in the training dataset of 142 stage I
patients. In each cross-validation, we identified a gene signature
that gives the highest prediction accuracy and recorded genes
entered in the identified signature. We then counted the frequency
of genes present in all of the cross-validation sets. Genes with a
frequency .50% were selected to comprise the final signature
(Table 2). Finally, risk scores were estimated for each of 142
samples in the training dataset using the expression data of these
51 genes. Based on the risk scores, we classified these patients into
high and low risk groups and performed Kaplan-Meier survival
analyses on these stratified samples. As shown in Fig. 1,
recurrence-free survival was significantly different between the
high and low-risk groups as defined by the risk scores using the
expression data (P,1e-16). Kaplan-Meier survival curves could
not distinguish poorer survival among stage IB from stage IA
NSCLC (P=0.38). To evaluate their predictive performance, we
further calculated the time-dependent area under the ROC curves
based on either stage information or the estimated risk scores of
the patients (Fig. 1C). The expression-based stratified approach
performs much better than the pathological staging method. Our
approach achieves AUCs close to 90% while the Cox model with
stage information results in very low AUCs,60%.
Validation of the recurrence signature in independent
test sets
To determine if the 51-gene signature could predict patients
likely to develop tumor recurrence in independent samples, we
applied it to four independent datasets (Table 1). Specifically, a
risk score for each patient was calculated based on the expression
levels of the 51-gene signature; poor outcome was defined as risk
score .0 and good outcome was defined as risk score ,0. Cox
proportional hazards modeling was used to classify patients in each
Table 2. Genes related to tumor recurrence of stage I NSCLC.
Genes Function HR Genes Function HR
AU148154 0.5792 NM_018600 1.5353
B4GALT1 Cell adhesion 1.8344 OCA2 cell differentiation 1.4181
CGB cell death 1.3312 PADI3 terminal differentiation of the epidermis 1.5470
CHST12 1.4697 RPRM negative regulation of progression through cell cycle 1.4748
CLEC11A positive regulation of cell proliferation 1.6334 SH3YL1 1.5522
COL2A1 negative regulation of apoptosis, Cell adhesion 1.5701 SLC27A2 PPAR signaling pathway 1.4456
CYP2A6 nicotine metabolism 1.2751 SLC35F5 1.4836
DENND1A synaptic vesicle endocytosis 1.4545 SNAPC2 transcription from RNA polymerase II promoter 1.5725
DIO1 1.5142 SPTBN2 cell death 1.6520
DOCK6 1.6545 STRN3 1.3969
EPHB6 Loss of expression in metastatic melanoma 1.4146 SUSD4 1.4464
FZD9 G-protein coupled receptor protein signaling pathway 1.2810 TCF3 transcription factor activity 1.5250
GLE1 export mRNA from nucleus to cytoplasm 1.4920 TET3 tet oncogene family member 3 1.6322
GTF3C2 transcription factor 1.6350 THBS1 Cell adhesion, blood vessel development 1.3397
INF2 Rho GTPase binding 1.4114 TRIM34 1.4886
KDM4B transcriptional target of hypoxia-inducible factor 1.7967 TRIM46 1.4355
SIK3 protein phosphorylation 0.5875 TRIP11 transcription from RNA polymerase II promoter 1.4917
GREB1L 1.4917 CELSR1 Cell adhesion 1.5144
KLK5 epidermis development 1.4736 UBE2D4 ubiquitination 1.4669
KRT81 keratin filament 1.3167 UBXN4 response to unfolded protein 1.4742
LENEP cell differentiation 1.5902 VKORC1 oxidoreductase activity 1.5498
MYOG cell differentiation 1.6048 ZBTB7B cell differentiation 1.5783
NFKBIL1 member of the I-kappa-B family 1.5875 ZNF365 1.5436
NLRP2 cell death 1.4080 MUC5AC induction of apoptosis, Cell adhesion 1.4135
NM_004876 FGFR2 cell growth 1.5516
FEZ2 cell projection organization and biogenesis 1.6395
doi:10.1371/journal.pone.0030880.t002
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signature was determined by AUC of time-dependent ROC
analysis and Somers’ Dxy rank correlation between estimated risk
score and real survival time.
Mayo Clinic dataset included 54 never smokers with stage I
NSCLC, and most of which were adenocarcinomas. The risk
scores estimated by expression of 46 genes presented on Illumina
DASL assay have high correlation with the real survival time
(Dxy=20.853). AUC from time-dependent ROC analysis is
about 88% using the risk scores and 57% using stage information.
Predicted poor-outcome patients had a significantly worse
recurrence-free survival (log-rank P=4.37e26) (Fig. 2A). In the
testing dataset GSE5843 with 46 stage I adenocarcinoma, the gene
signature has an overall accuracy of 86% and the predicted high
risk scores are significantly associated with shorter observed time
to recurrence (log-rank P=7e29; Fig. 2B). In contrast, the
accuracy of predicting recurrence using stage information alone is
66%.
Only 32 of 51 genes in the recurrence signature are available on
the early-generation Affymetrix U95A microarray used in the
WUSTL testing dataset. Despite incomplete representation, the
signature we identified still has a good performance with the AUCs
around 85% in predicting recurrence. Kaplan-Meier analysis
confirmed that the predicted high-risk group have a significantly
shorter time to recurrence than the low-risk group (P=7.36e25)
(Fig. 2C).
GSE8894 is the largest testing dataset, including 62 adenocar-
cinomas and 76 squamous cell carcinomas. We evaluated the
performance of our signatures in predicting recurrence-free
survival in adenocarcinomas and squamous cell carcinomas
separately. Cox model with risk scores estimated by expression
data give a good predictive performance (Dxy=20.706) with the
AUCs of more than 85% for adenocarcinoma (Fig. 2D). In
squamous cell carcinomas, we obtained a little less predictive
AUCs, but the predicted high-risk group still had a significantly
shorter time to recurrence (Dxy=20.678 and P=3.48e27, Fig.
S2).
Significant pathways related to recurrence
Pathway-based survival analyses identified 97 significant
prognostic KEGG pathways related to recurrence (p,10
25,
Table S2). Table 3 listed the top 30 important pathways, including
multiple important cancer-related pathways such as cell adhesion
molecules, the Jak-STAT signaling pathway, p53 signaling
pathway, MAPK signaling pathway, Wnt signaling pathway,
mTOR signaling pathway and ErbB signaling pathway. The
differentially expressed genes associated with recurrence identified
by our survival analysis were also enriched in biological process of
cell adhesion.
Discussion
A major limitation of current clinical prognostic indicators is
their inability to predict which patients with early-stage disease will
develop disease recurrence. We previously described a 64-gene
signature of overall survival in stage I NSCLC capable of
predicting outcome in independent samples [15]. In this study,
we sought to determine if a comparable signature existed in stage I
adenocarcinomas to predict recurrence-free survival in lung
cancer. Using microarray datasets of stage I lung cancer from
the Director’s Challenge Consortium, we further developed a new
gene-expression signature predictive of recurrence of stage I
NSCLC patients. We used samples from four institutions in the
Director’s Challenge Consortium as the training dataset to identify
Figure 1. Survival analyses of the training set of 142 stage I
denocarcinomas. (A) Kaplan-Meier survival curves for two groups of
patients with stage IA or IB. (B) Kaplan-Meier survival curves for the two
groups of patients defined by having positive (high risk) or negative
(low risk) risk scores of recurrence-free survival. The risk scores were
estimated with 15 principle components based on the model using 51
recurrence-free survival-related genes. (C) The area under the curve
(AUC) of time-dependent ROC analysis for survival models based on
stage information or 51-gene expression data respectively. Time is
indicated in months on the x-axis, cumulative survival is indicated on
the y-axis. Tick marks, patients whose data were censored at last follow-
up.
doi:10.1371/journal.pone.0030880.g001
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disease heterogeneity and confounding effects from treatments, we
used a total of 142 stage I lung adencarcinomas patients without
adjunctive chemo- or radiation-therapy as the training samples
(Table 1). To integrate the gene expression data from the four
institutions, we applied DWD method to remove systematic
differences that were present within this dataset. Subsequently, we
identified 104 genes whose expression was correlated with
recurrence-free survival. As expected, the gene ontology compo-
sition of these genes has biological relevance to disease recurrence,
such as cell adhesion, apoptosis, and cell proliferation.
Using a partial Cox regression model-based forward selection
procedure, we identified a 51-gene signature from 104 differen-
tially expressed genes. The identified signature is highly predictive
of tumor recurrence in patients with stage I lung adenocarcino-
mas. One of the potential issues in developing a predictive
signature is model overfitting to the training dataset. This may
result in a signature that reflects the characteristics of the training
samples and cannot accurately predict outcome in independent
samples. To avoid model overfitting, we further used leave-one-out
cross-validation procedure to generate the gene signature of
recurrence in the training dataset. Consequently, it is also critical
to validate the prediction signature in independent datasets. We
therefore applied our signature in four independent datasets to
evaluate its prediction performance. In general, our signature is
highly predictive of which patients with stage I lung adenocarci-
nomas will develop recurrence disease and it achieves more than
85% in AUC across different independent datasets. The test set
GSE8894 included both adenocarcinomas and squamous cell
carcinomas; 36% of samples were advanced stage patients. A
recent study showed that lung cancer recurrence depends on
histological subtype in the stage IA non-small cell lung cancer,
with higher rates occurring among patients with non-squamous
carcinomas [21]. Interestingly, the 51-gene signature was also
highly predictive of recurrence free survival of squamous cell
carcinomas in the dataset GSE8894 although it was initially
derived from stage I adenocarcinoma.
The identified differentially expressed genes in the present study
may provide new insights into therapeutic targets and treatment of
recurrence disease in stage I lung tumors. Among them, FBXW7
targets mTOR for degradation and cooperates with PTEN in
tumor suppression [22]. The low FBXW7 expression group
showed a significantly poorer prognosis than in the high expression
group in patients with colorectal cancer [23]. Its lower expression
were also associated with decreased recurrence-free survival in
stage I lung adenocarcinomas (Table S1). Another interesting
candidate is FGFR2, which is one of transmembrane tyrosine
kinase receptors involved in signaling via interaction with the
fibroblast growth factor (FGF) family. The fibroblast growth factor
(FGF) family, which includes important regulatory factors of cell
growth and differentiation, has been found to be involved in
embryonic development, angiogenesis and tumorigenesis. It has
been suggested that FGFR2 plays an important role in the
tumorigenesis of gastric cancer. We found the increased expression
in FGFR2 is associated with poor outcome of stage I lung cancer
patients. A newly developed small-molecule-acting FGFR inhib-
itor, Ki23057, can compete with ATP for the binding site in the
kinase [24]. It will be interesting to see if such an inhibitor can
improve the outcome of patients who are predicted to be at a high-
risk of recurrence with the gene-expression signature. In addition,
we also identified three splicing factors SFRS2IP, SFRS14 and
SFRS18 associated with disease outcome. All three splicing factors
are members of the arginine/serine-rich family and worthy of
further study.
Our pathway-based survival analyses found that leukocyte
transendothelial migration, protein processing in endoplasmic
reticulum and cell adhesion molecules (CAMs) are the top three
KEGG pathways highly correlated with recurrence-free survival
Figure 2. Validation of the 51-gene signature in four independent datasets. Kaplan-Meier survival analysis was performed in low (full red
line) and high (dashed blue line) risk patient groups defined by the 51-gene classifier. AUC for survival models based on stage (dashed red line) or 51-
gene classifier (full black line) was also compared. The testing dataset GSE8894 do not have available stage information and all patients in the WUSTL
dataset are stage IB. So the time dependent ROC using stage information in these two datasets could not be calculated; all set at 0.5 instead. Tick
marks, patients whose data were censored at last follow-up.
doi:10.1371/journal.pone.0030880.g002
Table 3. Top 30 significant prognostic KEGG pathways
related to recurrence.
KEGG
pathway Pathway annotation
Gene
number P value
hsa04670 Leukocyte transendothelial migration 116 1.01E-13
hsa04141 Protein processing in endoplasmic reticulum 166 3.99E-13
hsa04514 Cell adhesion molecules (CAMs) 113 7.23E-12
hsa00230 Purine metabolism 161 1.44E-11
hsa03013 RNA transport 151 2.77E-11
hsa04630 Jak-STAT signaling pathway 155 3.14E-11
hsa03040 Spliceosome 127 3.82E-11
hsa04660 T cell receptor signaling pathway 108 6.73E-11
hsa04722 Neurotrophin signaling pathway 127 1.11E-10
hsa04144 Endocytosis 195 1.24E-10
hsa04380 Osteoclast differentiation 128 1.29E-10
hsa04730 Long-term depression 69 1.68E-10
hsa04115 p53 signaling pathway 68 2.96E-10
hsa00190 Oxidative phosphorylation 132 3.62E-10
hsa04010 MAPK signaling pathway 267 4.65E-10
hsa04910 Insulin signaling pathway 138 7.16E-10
hsa04930 Type II diabetes mellitus 48 8.82E-10
hsa04060 Cytokine-cytokine receptor interaction 264 1.10E-09
hsa04530 Tight junction 132 2.48E-09
hsa04666 Fc gamma R-mediated phagocytosis 92 3.75E-09
hsa04310 Wnt signaling pathway 150 4.61E-09
hsa04020 Calcium signaling pathway 177 4.84E-09
hsa04150 mTOR signaling pathway 52 5.24E-09
hsa03008 Ribosome biogenesis in eukaryotes 77 5.49E-09
hsa03015 mRNA surveillance pathway 83 5.62E-09
hsa03010 Ribosome 91 5.78E-09
hsa04914 Progesterone-mediated oocyte maturation 86 7.37E-09
hsa05322 Systemic lupus erythematosus 122 9.24E-09
hsa04120 Ubiquitin mediated proteolysis 135 9.66E-09
hsa04012 ErbB signaling pathway 87 1.08E-08
doi:10.1371/journal.pone.0030880.t003
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significantly related to recurrence. Leukocytes cross the endothe-
lium lining the vasculature initiated by chemokine- and adhesion
molecule-induced intracellular signaling that controls adhesion,
spreading, and motility. At the same time, adherent leukocytes
trigger the endothelium, manipulating the barrier to promote their
transmigration into the underlying tissues [25]. CAMs are
gatekeepers for leukocyte transendothelial migration. Endothelial
cell intercellular CAMs expression is negatively correlated with
metastatic potential in lung cancer [26]. L1 cell adhesion molecule
(L1CAM) has potential prognostic value in pulmonary neuroen-
docrine tumors. Patients with high L1 expression have a higher
risk for recurrence compared with those with low L1 expression
[27]. The endoplasmic reticulum (ER) is an essential organelle
involved in many cellular functions including protein folding and
secretion. The ER plays a vital role in cellular protein quality
control by extracting and degrading proteins that are not correctly
folded or assembled into native complexes, i.e. ER-associated
degradation (ERAD) to ensure that only properly folded and
assembled proteins are transported to their final destinations. The
ER is also a major organelle for oxygen and nutrient sensing as
cells adapt to their microenvironment. The unfolded protein
response (UPR) is a cellular stress response related to the ER. It is
activated in response to an accumulation of unfolded or misfolded
proteins in the lumen of the ER. In this scenario, the UPR has two
primary aims: initially to restore normal function of the cell by
halting protein translation and activate the signaling pathways that
lead to increased production of molecular chaperones involved in
protein folding. If these objectives are not achieved within a
certain time lapse or the disruption is prolonged, the UPR leads to
apoptosis [28]. Cell adhesion molecules (CAMs) pathway is much
more important than cell cycle and apoptosis in prognosis of
recurrence according to our results (Table 3). Determination of
CAMs expression as biomarker in future clinical trials may be
widely realized for cancer therapy.
In summary, we identified a 51-gene expression signature highly
predictive of tumor recurrence in stage I NSCLC and validated it
in four independent data sets. This gene expression signature has
the potential of the identification of high-risk individuals who
would perhaps benefit most from adjuvant treatment in early-stage
lung cancers. If patients predicted to be at high risk of recurrent
disease by genomic signatures are shown in clinical trials to be
those who benefit most from adjuvant treatment, the clinical pay-
off for genomic tumor analyses will have been realized.
Supporting Information
Figure S1 PRISMA flow diagram. PRISMA 2009 flow
diagram regarding the data selection. The databases used for the
search of microarray data were GEO, ArrayExpress and
caARRAY. In the research, we used the keywords: ‘‘lung’’,
‘‘cancer’’, ‘‘gene’’ and ‘‘survival’’.
(EPS)
Figure S2 Validation of the 51-gene signature in the
subset of squamous cell carcinomas in GSE8894.
Comparison of survival estimates in low ( full red line) and high
(dashed blue line) risk patient groups defined by the 51-gene classifier
is shown in the left panel. AUC for survival models based on 51-
gene classifier ( full black line) is shown in the right panel. The stage
information is not available in GSE8894, and the AUC was set at
0.5. Tick marks, patients whose data were censored at last follow-
up.
(EPS)
Figure S3 KEGG pathway-based survival analyses in
the training set of 142 stage I adenocarcinomas. Kaplan-
Meier survival analysis was performed in low and high risk patient
groups stratified by the risk scores that were estimated from the
expression of genes in each pathway. (A) Leukocyte transendothe-
lial migration, (B) Protein processing in endoplasmic reticulum,
and (C) Cell adhesion molecules. Time is indicated in months on
the x-axis, cumulative survival is indicated on the y-axis. Tick
marks, patients whose data were censored at last follow-up.
(EPS)
Table S1 Differentially expressed genes related to
recurrence.
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Table S2 Significant KEGG pathways related to recur-
rence.
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